黑色素-话题@MedSci

#黑色素#

1110篇内容 | 3077人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1565123, encodeId=487115651238d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=60, createdTime=2022-02-17, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559114, encodeId=cacc1559114df, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=68, createdTime=2022-02-17, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565122, encodeId=aca21565122c5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=23, createdTime=2022-01-17, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559113, encodeId=02e315591130b, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=23, createdTime=2022-01-17, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565121, encodeId=6f431565121cb, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征, objectType=article, longId=293979, objectId=c08c2939e93e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c08c2939e93e, replyNumber=0, likeNumber=85, createdTime=2022-01-16, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c08c2939e93e, moduleTitle=Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c08c2939e93e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559112, encodeId=1c73155911230, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征, objectType=article, longId=293979, objectId=c08c2939e93e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c08c2939e93e, replyNumber=0, likeNumber=123, createdTime=2022-01-16, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c08c2939e93e, moduleTitle=Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c08c2939e93e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565120, encodeId=73e6156512083, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？, objectType=article, longId=293533, objectId=069e293533fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=069e293533fd, replyNumber=0, likeNumber=66, createdTime=2022-01-08, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=069e293533fd, moduleTitle=NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=069e293533fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559111, encodeId=b1161559111b4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？, objectType=article, longId=293533, objectId=069e293533fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=069e293533fd, replyNumber=0, likeNumber=68, createdTime=2022-01-08, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=069e293533fd, moduleTitle=NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=069e293533fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565119, encodeId=cd3315651196a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, objectType=article, longId=292248, objectId=3be42922488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be42922488a, replyNumber=0, likeNumber=70, createdTime=2021-12-21, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be42922488a, moduleTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3be42922488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559110, encodeId=9dc81559110ed, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, objectType=article, longId=292248, objectId=3be42922488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be42922488a, replyNumber=0, likeNumber=68, createdTime=2021-12-21, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be42922488a, moduleTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3be42922488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565118, encodeId=4b55156511896, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险, objectType=article, longId=221745, objectId=4fd3221e4539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fd3221e4539, replyNumber=0, likeNumber=151, createdTime=2021-12-10, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fd3221e4539, moduleTitle=J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fd3221e4539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559109, encodeId=6392155910930, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险, objectType=article, longId=221745, objectId=4fd3221e4539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fd3221e4539, replyNumber=0, likeNumber=0, createdTime=2021-12-10, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fd3221e4539, moduleTitle=J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fd3221e4539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565117, encodeId=c49d156511e7c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Front Oncol：真实世界研究分析黑色素瘤患者抗PD-1治疗免疫相关不良事件与疗效的关系, objectType=article, longId=221570, objectId=2dff2215e066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dff2215e066, replyNumber=0, likeNumber=105, createdTime=2021-12-07, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dff2215e066, moduleTitle=Front Oncol：真实世界研究分析黑色素瘤患者抗PD-1治疗免疫相关不良事件与疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dff2215e066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559108, encodeId=63661559108fc, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Front Oncol：真实世界研究分析黑色素瘤患者抗PD-1治疗免疫相关不良事件与疗效的关系, objectType=article, longId=221570, objectId=2dff2215e066, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dff2215e066, replyNumber=0, likeNumber=86, createdTime=2021-12-07, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dff2215e066, moduleTitle=Front Oncol：真实世界研究分析黑色素瘤患者抗PD-1治疗免疫相关不良事件与疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dff2215e066)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565116, encodeId=3d021565116a4, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=2021CSCO专家采访黑色素瘤前言进展和热点话题, objectType=article, longId=221255, objectId=121d22125520, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121d22125520, replyNumber=0, likeNumber=57, createdTime=2021-12-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121d22125520, moduleTitle=2021CSCO专家采访黑色素瘤前言进展和热点话题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121d22125520)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559107, encodeId=4e93155910e3d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=2021CSCO专家采访黑色素瘤前言进展和热点话题, objectType=article, longId=221255, objectId=121d22125520, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121d22125520, replyNumber=0, likeNumber=56, createdTime=2021-12-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121d22125520, moduleTitle=2021CSCO专家采访黑色素瘤前言进展和热点话题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121d22125520)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565115, encodeId=2de4156511574, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率, objectType=article, longId=221202, objectId=9a872212023e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a872212023e, replyNumber=0, likeNumber=75, createdTime=2021-11-30, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a872212023e, moduleTitle=eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a872212023e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559106, encodeId=9825155910616, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率, objectType=article, longId=221202, objectId=9a872212023e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a872212023e, replyNumber=0, likeNumber=0, createdTime=2021-11-30, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a872212023e, moduleTitle=eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a872212023e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559105, encodeId=221c155910597, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, objectType=article, longId=221149, objectId=c9542211494e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9542211494e, replyNumber=0, likeNumber=83, createdTime=2021-11-28, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9542211494e, moduleTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9542211494e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565114, encodeId=961e1565114ff, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, objectType=article, longId=221149, objectId=c9542211494e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9542211494e, replyNumber=0, likeNumber=73, createdTime=2021-11-28, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9542211494e, moduleTitle=J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9542211494e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黑色素

2020-05-29

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2022-02-17

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2022-02-17

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-01-17

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-01-17

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征

2022-01-16

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Nat Med：黑色素瘤患者与免疫检查点阻断毒性相关的T细胞特征

2022-01-16

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？

2022-01-08

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NEJM：未经治疗晚期黑色素瘤患者该采用瑞拉利单抗-纳武单抗组合治疗还是单独纳武单抗治疗？

2022-01-08

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法

2021-12-21

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法

2021-12-21

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险

2021-12-10

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

J Clin Invest：点阵激光换肤治疗可有效降低衰老皮肤非黑色素瘤皮肤癌的发病风险

2021-12-10

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Front Oncol：真实世界研究分析黑色素瘤患者抗PD-1治疗免疫相关不良事件与疗效的关系

2021-12-07

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Front Oncol：真实世界研究分析黑色素瘤患者抗PD-1治疗免疫相关不良事件与疗效的关系

2021-12-07

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

2021CSCO专家采访黑色素瘤前言进展和热点话题

2021-12-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

2021CSCO专家采访黑色素瘤前言进展和热点话题

2021-12-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率

2021-11-30

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

eLife：小黑痣是怎么癌变成黑色素瘤的？与周围皮肤中的环境信号有关反应，提高移植细胞的生存率

2021-11-30

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤

2021-11-28

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

J Clin Oncol：纳武单抗联合伊匹单抗治疗晚期黑色素瘤

2021-11-28

科室
- - 订阅+
  - 更多科室
工具
服务